Vertex Pharmaceuticals Incorporated

VRTX Details

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is a multinational biotechnology firm focused on discovering and developing small-molecule medicines to treat acute diseases. Its primary medications for cystic fibrosis are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Vertex therapies remain the standard of treatment globally.

Why should Investors Sell?

• High Cash Cycle Days: The company has 123 cash conversion days in Q3FY2021, higher than the industry median of 75 days.
• Business Risk: The company is exposed to business and financial risk, which might impact the revenue part and slow down the margins.
• COVID 19 Restrictions: From the global perspective, the company is still risky because of covid restrictions, and it will put disruptions in demand and supply, which will adversely impact financials.
• Technical Bearish Indicators: The company's current market price is USD 234.06, trailing above 50 and 200 DMA and leaning towards its 52 Weeks high of USD 242.99. Furthermore, the 14-days RSI of ~82.23 approaches overbought territory and indicates a correction in the stock price.

Valuation Methodology: EV/EBITDA Multiple Based Relative Valuation

(Analysis by Kalkine Group)

VRTX Daily Technical Chart (Source: REFINITIV)

Stock Recommendation:

VRTX's stock price has surged 24.48% in the past three months and is currently leaning towards the higher-band of the 52-week range of USD 176.36 to USD 242.99. The stock is currently trading above its 50 and 200 DMA levels, and its RSI Index is 82.23, indicating an overbought zone. We have valued the stock using the EV/EBITDA multiple-based relative valuation methodology and arrived at a target price of USD 205.03.

Considering the risk of disruption in the supply chain, current valuation, and bearish technical indicators, we believe the decent business fundamentals are adequately reflected at current trading levels. Hence, we recommend a "Sell" rating on the stock at the closing price of USD 234.06, down 1.39%, as of January 14, 2022.

* The reference data in this report has been partly sourced from REFINITIV.

* All forecasted figures and industry information have been taken from REFINITIV.

Disclaimer

The advice given by Kalkine Canada Advisory Services Inc. and provided on this website is general information only and it does not take into account your investment objectives, financial situation and the particular needs of any particular person. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. The website www.kalkine.ca is published by Kalkine Canada Advisory Services Inc. The link to our Terms & Conditions has been provided please go through them. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.